If you have been reading about research peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
== Gameplay == As with previous Half-Life games, Episode Two is played in the first person as Gordon Freeman against transhuman troops, known as the Combine, and other hostile alien creatures. Levels are linear but add a more open environment, consisting of puzzles and first-person shooter (FPS) gameplay. Sequences involving vehicles are interspersed throughout the game, breaking up moments of combat. One of the focal points was the increased use of vehicles in open areas. However, the game retains its original linear style until the final battle. Episode Two has more puzzles than Episode One; the sequence in which the player must cross a damaged bridge was the largest physics puzzle in the series up to that point. As in the previous two games, Episode Two features numerous "achievements" (similar to PlayStation 3's Trophies and Xbox Live's Achievements) for carrying out certain tasks. Some are essential to game progress, such as helping fight off an antlion invasion, or defeating the first Hunters. Others are optional tricks or feats the player can perform, such as killing a Combine soldier with their own grenade or running down a certain number of enemies with the car. Episode Two features a new enemy, the Hunter, which is seen briefly in a recorded message in Episode One. The Hunter is one of the most dangerous enemies and serves as means of emotional development for Alyx Vance. The Hunter is a powerful and resilient enemy which players must often run from while seeking a means to fight back; Episode Two's environments are designed with this in mind.
Valproate is a weak or low-potency histone deacetylase inhibitor, specifically of the class I HDAC1, HDAC2, HDAC3, and HDAC8, but not of other HDACs. Earlier studies found a wide range of inhibitory potencies of valproate against HDACs, ranging from low micromolar to millimolar concentrations, but subsequent work with improved methodology has supported greater inhibitory potencies, with IC50Tooltip half-maximal inhibitory concentration values in the range of 36 to 219 μM for the class I HDACs. For comparison, valproate was found to be 4- to 46-fold less potent in inhibiting the class I HDACs relative to butyric acid (butyrate). By inhibiting HDACs, valproate promotes more transcriptionally active chromatin structures, that is it exerts an epigenetic effect. This has been proven in mice: Valproic acid induced histone hyperacetylation had brain function effects on the next generation of mice through changes in sperm DNA methylation. Intermediate molecules include VEGF, BDNF, and GDNF.
By July 2019, this has not happened, according to The Record. Critics raised concerns that Hydro One will not experience stability as Premier Ford's government has a "record of reaching in to exert control." On March 21, 2019, Minister Rickford tabled Bill 87, the Fixing the Hydro Mess Act, which was given royal assent on May 9. Bill 87 overhauled the Ontario Energy Board and eliminated the Liberal's 2017 Fair Hydro Plan which the PC's said would save $442 million. The Liberal Plan "subsidized electricity with borrowed money" in response to a "public outcry over soaring hydro rates, particularly in rural areas." The Liberals created the Ontario Power Generation Inc (OPG Trust) as the Financial Services Manager to manage the debt. Bonnie Lysyk, the Auditor General, released a special report on October 17, 2017, which said the "structure of the plan" was in violation of the provincial government's accounting rules. She said that the Plan, which committed the government to discount consumer electricity rates for ten years, would cost the province "$21 billion in interest over the next 30 years." The 2017 AG report said that it would cost $4 billion more on the $18.4 billion loan to use the Ontario Power Generation (OPG Trust) than if the province took out the loan because the province would have a lower interest rate than the OPG Trust. The Ford government said that they would maintain [the] 25 per cent time-of-use rates, that was part of the Liberal's Fair Hydro Plan.
=== Antibiotics === Empiric antibiotics are usually initiated as soon as the diagnosis of NSTI has been made. They are then changed to culture-guided antibiotic therapy. In the case of NSTIs, empiric antibiotics are broad-spectrum, covering gram-positive (including MRSA), gram-negative, and anaerobic bacteria. Often, a combination of clindamycin, daptomycin, IV vancomycin, and gentamicin is used. Gram-negative coverage may entail the use of fluoroquinolones, piperacillin/tazobactam, or carbapenems. Despite multiple studies, there is no consensus on how long antibiotics should be given. Generally, antibiotics are administered until surgeons decide that no further debridement is needed, and the patient no longer shows any systemic signs of infection from a clinical and laboratory standpoint. Evidence regarding the efficacy of treatment and adverse effects is also unclear.
Frederick McKinley Jones (May 17, 1893 – February 21, 1961) was an American inventor, entrepreneur, engineer, winner of the National Medal of Technology, and an inductee of the National Inventors Hall of Fame. He innovated mobile refrigeration technology. Jones received 61 patents, including 40 for refrigeration technology, and also revolutionized the cinema industry by creating a superior sound system for projectors at the time. Jones co-founded Thermo King and also served as a sergeant in World War I. Due to his contributions to refrigeration technology, Jones is called the "Father of Refrigerated Transportation", and the "King of Cool".
Sources: en.wikipedia.org
The normal form of ice on the surface of Earth is ice Ih, a phase that forms crystals with hexagonal symmetry. Another with cubic crystalline symmetry, ice Ic, can occur in the upper atmosphere. As the pressure increases, ice forms other crystal structures. As of 2024, twenty have been experimentally confirmed and several more are predicted theoretically. The eighteenth form of ice, ice XVIII, a face-centred-cubic, superionic ice phase, was discovered when a droplet of water was subject to a shock wave that raised the water's pressure to millions of atmospheres and its temperature to thousands of degrees, resulting in a structure of rigid oxygen atoms in which hydrogen atoms flowed freely. When sandwiched between layers of graphene, ice forms a square lattice. The details of the chemical nature of liquid water are not well understood; some theories suggest that its unusual behavior is due to the existence of two liquid states.
The following is a partial list of the "D" codes for Medical Subject Headings (MeSH), as defined by the United States National Library of Medicine (NLM). This list continues the information at List of MeSH codes (D12.776). Codes following these are found at List of MeSH codes (D20). For other MeSH codes, see List of MeSH codes. The source for this content is the set of 2006 MeSH Trees from the NLM.
== Evolution == Phylogenetic analyses suggest that DBP diverged from ancestral albumin through gene duplication events that occurred after the separation of jawless fish (cyclostomes) from jawed vertebrates approximately 450 million years ago. This timeline is supported by the apparent absence of DBP-like proteins in lampreys and hagfish, though these organisms retain vitamin D transport capability through alternative lipoprotein-mediated mechanisms. DBP is found throughout jawed vertebrates, from bony fish to mammals, suggesting its evolution coincided with the development of calcified skeletons and more sophisticated calcium homeostasis requirements.
=== Pregnancy === In pregnancy, the vulva and vagina take on a bluish coloring due to venous congestion. This appears between the eighth and twelfth week and continues to darken as the pregnancy continues. Estrogen is produced in large quantities during pregnancy and this causes the vulva to become enlarged. The vaginal opening and the vagina are also enlarged. After childbirth, a vaginal discharge known as lochia is produced and continues for about ten days.
Sources: en.wikipedia.org
Ruffini endings respond to regular stretching and to slow sustained pressure. In addition to initiating fascial relaxation, they contribute to full-body relaxation by inhibiting sympathetic activity which slows down heart rate and respiration. When contraction persists, fascia will respond with the addition of new material. Fibroblasts secrete collagen and other proteins into the extracellular matrix where they bind to existing proteins, making the composition thicker and less extensible. Although this potentiates the tensile strength of the fascia, it can unfortunately restrict the very structures it aims to protect. The pathologies resulting from fascial restrictions range from a mild decrease in joint range of motion to severe fascial binding of muscles, nerves and blood vessels, as in compartment syndrome of the leg. However, if fascial contraction can be interrupted long enough, a reverse form of fascial remodeling occurs. The fascia will normalize its composition and tone and the extra material that was generated by prolonged contraction will be ingested by macrophages within the extracellular matrix. Like mechanoreceptors, chemoreceptors in deep fascia also have the ability to promote fascial relaxation. We tend to think of relaxation as a good thing, however fascia needs to maintain some degree of tension. This is especially true of ligaments. To maintain joint integrity, they need to provide adequate tension between bony surfaces. If a ligament is too lax, injury becomes more likely.
== Research == Stanozolol has been investigated in the treatment of a number of dermatological conditions including urticaria, hereditary angioedema, Raynaud's phenomenon, cryofibrinogenemia, and lipodermatosclerosis.
30 May to 1 July Operation Lavarack was a reconnaissance in force conducted by the 6th Battalion, Royal Australian Regiment/Royal New Zealand Infantry Regiment (ANZAC) north of Nui Dat. The operation resulted in 102 PAVN/VC and 3 ANZACs killed.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.